Newsmeme!
Discover News you didn't know existed
Phase Ii Clinical Trial
News
Related Video News
No related video news stories found.
Related Videos
No related videos found.
CENTRAL NY BUSINESS NEWS
Published December 5, 2008, 2:27 am, The Post-Standard
• UAW: Bail Out Detroit . . . and DeWitt A decision by Congress against providing $34 billion in bridge loans to the Big Three automakers would have an immediate effect on the New Process Gear transmission parts plant that would spread throughout Central New York's economy, a union leader said Thursday.
TorreyPines' NGX426 meets endpoints in reducing spontaneous pain
Published December 5, 2008, 1:51 am, PharmaBiz
TorreyPines Therapeutics, Inc announced that oral administration of NGX426, an AMPA/kainate-type glutamate receptor antagonist, demonstrated a statistically significant reduction in spontaneous pain, hyperalgesia (abnormally increased pain state) and allodynia (pain resulting from normally non-painful stimuli to the skin) compared to placebo following intradermal injections of capsaicin in a ...
Symphogen And Meiji Seika Kaisha Ltd. Achieve Milestone In Discovery Collaboration For Recombinant Polyclonal ...
Published December 4, 2008, 11:15 am, Medical News Today
Symphogen A/S and Meiji Seika Kaisha Ltd. (TSE: 2202) announced today the advancement of their collaboration for the discovery, development and commercialization of a recombinant polyclonal antibody therapeutic, Sym006, that targets an undisclosed bacterial pathogen. The companies, who initiated the collaboration in December 2006, are moving the program into preclinical development.
Two-Year Follow-Up Data Demonstrates Preservation of Adequate Mitral Valve Area in Patients Treated with the ...
Published December 4, 2008, 11:07 am, PR Newswire via Yahoo! Finance
Long-term data published in EuroIntervention showed that the expected decrease in Mitral Vale Area after repair with the MitraClip® system to correct mitral regurgitation is not associated with clinically significant mitral stenosis.
Kiadis Pharma Announces Positive Clinical Results for ATIR(TM) in Mismatched Bone Marrow Transplantations
Published December 4, 2008, 7:29 am, PR Newswire via Yahoo! Finance
Biopharmaceutical company Kiadis Pharma announces today that it has successfully completed treatment of the last patient on its ATIR phase I/II clinical trial. ATIR, a donor lymphocyte cell based product, is under development to prevent acute Graft versus Host Disease and allow early immune reconstitution following a mismatched bone marrow transplantation.
ConjuChem's PC-DAC(TM):Exendin-4 Lowers Glucose And Weight In Phase II Diabetes Trials
Published December 4, 2008, 7:13 am, Medical News Today
ConjuChem Biotechnologies, Inc. (TSX:CJB) announced preliminary results today showing that its Type 2 diabetes product, PC-DAC(TM):Exendin-4, achieved statistically significant reductions in HbA1c and weight in its two Phase II clinical trials.
Osiris Completes Enrollment in First Worldwide Phase III Stem Cell Trial
Published December 4, 2008, 6:32 am, Centre Daily Times
Osiris Therapeutics, Inc . (NASDAQ:OSIR) announced today that it has completed patient enrollment in its Phase III pivotal trial evaluating Prochymal for the treatment of steroid-refractory acute Graft versus Host Disease (GvHD), a life threatening complication of bone marrow transplantation. Prochymal is a proprietary formulation of adult mesenchymal stem cells (MSCs) designed to provide ...
OPKO Health Announces Completion of Enrollment for Its Phase III Clinical Trial of Bevasiranib for Treatment of AMD
Published December 4, 2008, 6:16 am, Business Wire via Yahoo! Finance
MIAMI----OPKO Health, Inc. announced today that it has completed enrollment in the Company’s Phase III clinical trial of bevasiranib for the treatment of wet age-related macular degeneration .
Jonathan Lewis, MD, PhD, Appointed to Scientific Advisory Council of the Hope Funds for Cancer Research
Published December 4, 2008, 6:00 am, Business Wire via Yahoo! Finance
NEW YORK & NEWPORT, R.I.----ZIOPHARM Oncology, Inc. and the Hope Funds for Cancer Research announced today that Jonathan Lewis, MD, PhD, Chief Executive and Medical Officer of ZIOPHARM, has been appointed to the Hope Funds’ newly formed Scientific Advisory Council, a permanent committee of the board.
Osiris Completes Enrollment in First Worldwide Phase III Stem Cell Trial
Published December 4, 2008, 6:00 am, Business Wire via Yahoo! Finance
COLUMBIA, Md.----Osiris Therapeutics, Inc. announced today that it has completed patient enrollment in its Phase III pivotal trial evaluating Prochymal for the treatment of steroid-refractory acute Graft versus Host Disease , a life threatening complication of bone marrow transplantation.
Related News Resources:
> HGH News
News Directory
Get started fast by using a pre-defined news directory category
|
Breaking News
and Top Stories |
Business
Earnings, Economy, Personal Finance, and Stock Markets |
Entertainment
Books, Celebrity, Fashion, Movies, Music, Television, and Theatre |
Health
Aging, Diseases, Medical Conditions, Medications, Sexual Health, and Weight Loss |
Politics
Congress, Supreme Court, and White House |
|
Science
Animals, Astronomy, Biotechnology, Space, and Weather |
Sports
Baseball, Basketball, Boxing, Football, Golf, Hockey, Motor Sports, Soccer, and Tennis |
Technology
Communications, Hardware, Internet, Personal Technology, and Software |
United States
and Crimes and Trials |
World
Africa, Antartica, Asia, Australia, Canada, Europe, Latin America, and Middle East |